电子患者报告结果 (ePRO) 症状监测可能支持免疫检查点抑制剂 (ICI) 的安全递送。对于常规护理中应监测哪些副作用尚未达成共识。我们的目标是制定一份 ICI 副作用的优先列表，以纳入 ePRO 系统，并将其与现有的 ICI 特定患者报告结果测量 (PROM) 进行比较。我们进行了两轮修改后的 Delphi 调查。参与者是已经接受/正在接受 ICI 或管理医疗保健专业人员 (HCP) 的患者（或其护理人员）。第 1 轮 (R1) 副作用是根据文献综述和现有 PROM 产生的。在 R1 中，参与者按照李克特五点量表对 ePRO 系统中 63 种 ICI 副作用的重要性进行了评分。在第 2 轮 (R2) 中，参与者从 36 种副作用中排名出 10 种最重要的副作用。根据现有 PROM 进行优先列表的内容映射。在 R1 中，47 名患者、9 名护理人员和 58 名 HCP 做出了回应。超过 75% 的参与者将 28 种副作用评为重要 (I)/非常重要 (VI)，并包含在 R2 中。十个被 <50% 的参与者评为 I/VI 并被排除。 50%-75% 的参与者对 25 项进行了 I/VI 评级，并在 HCP 圆桌会议上进行了讨论，以确定是否纳入 R2。在 R2 中，39 名患者、11 名护理人员和 42 名 HCP 将癫痫发作、呼吸急促、胸痛、腹泻和皮疹列为需要监测的最重要副作用。内容映射显示优先列表与现有 PROM 之间存在显着差异。我们开发了一个由消费者和临床医生驱动的 36 种 ICI 副作用优先列表，以包含在未来的 ePRO 系统中。这一过程强调了广泛的利益相关者参与副作用选择和严格识别临床重要副作用以确保内容有效性和临床实用性的重要性。

Electronic patient-reported outcome (ePRO) symptom monitoring may support the safe delivery of immune checkpoint inhibitors (ICI). There is no consensus on which side effects should be monitored in routine care. We aimed to develop a prioritized list of ICI side effects to include in ePRO systems and compare this to existing ICI-specific patient-reported outcome measures (PROMs).We conducted a two-round modified Delphi survey. Participants were patients (or their carers) who had received/were receiving ICI or managing health care professionals (HCPs). Round 1 (R1) side effects were generated from a literature review and existing PROMs. In R1, participants rated the importance of 63 ICI side effects in an ePRO system on a five-point Likert scale. In round 2 (R2), participants ranked the 10 most important side effects from 36 side effects. Content mapping of the prioritized list against existing PROMs was conducted.In R1, 47 patients, nine carers, and 58 HCPs responded. Twenty-eight side effects were rated important (I)/very important (VI) by >75% of participants and included in R2. Ten were rated I/VI by <50% of participants and excluded. Twenty-five were rated I/VI by 50%-75% of participants and discussed at an HCP roundtable to determine inclusion in R2. In R2, 39 patients, 11 carers, and 42 HCPs ranked seizures, shortness of breath, chest pain, diarrhea, and rash as the most important side effects for monitoring. Content mapping showed significant differences between the prioritized list and existing PROMs.We developed a consumer- and clinician-driven prioritized list of 36 ICI side effects to include in future ePRO systems. This process highlights the importance of broad stakeholder engagement in side-effect selection and rigorously identifying clinically important side effects to ensure content validity and clinical utility.